AdipoRon’s Impact on Alzheimer’s Disease—A Systematic Review and Meta-Analysis
Open accessThe DOI matches its Crossref record; 159 of the 159 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) remains a leading cause of cognitive decline and mortality worldwide, characterized by neurodegeneration, synaptic deficiencies, and neuroinflammation. Despite advancements in early detection, diagnosis, and treatment, AD presents substantial challenges due to its complex pathology, heterogeneity, and the limited efficacy of current therapies. Consequently, there is a pressing need for novel therapeutic agents to target the multifaceted aspects of AD pathology, enhance current treatments, and minimize adverse effects. AdipoRon, an adiponectin receptor agonist, has garnered interest for its potential neuroprotective effects, including reducing neuroinflammation, improving mitochondrial function, and mitigating tau hyperphosphorylation. This review aimed to evaluate the effects of AdipoRon-based adiponectin replacement therapy against AD, using a comprehensive approach grounded in the PICO framework—Population, Intervention, Comparison, and Outcomes. A total of six studies were reviewed, including in vitro and in vivo investigations examining AdipoRon’s impact on various AD models. These studies involved different cell lines and transgenic mouse models, assessing various outcomes such as cognitive function, neuroinflammation, tau phosphorylation, synaptic deficiencies, and relevant molecular pathways. By synthesizing data from these studies, our review thoroughly explains AdipoRon’s neuroprotective effects, mechanisms of action, and potential as a therapeutic agent for AD. This analysis aims to highlight the current state of knowledge, identify gaps in the research, and suggest directions for future studies and clinical applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Molecular Structure of AdipoRon. AdipoRon, with the molecular formula C27H28N2O3, has a molecular weight of 428.5 g/mol. Its exact mass is 428.20999276 Da, aligning with its monoisotopic mass. The compound exhibits high lipophilicity, with an XLogP3-AA value of 4.7, indicating it is more soluble in fats than water. It has one hydrogen bond donor and four hydrogen bond acceptors, suggesting its capacity for hydrogen bonding and potential interactions with other molecules. AdipoRon features eight rotatable bonds, reflecting its structural flexibility. Its topological polar surface area is 58.6 Å2, suggesting moderate polarity, influencing its ability to cross biological membranes. With a heavy atom count of 32, AdipoRon is relatively complex, and its complexity value of 582 further supports this. The compound is electrically neutral with a formal charge of 0 and lacks chiral centers, indicating no stereoisomerism. These properties highlight AdipoRon’s lipophilic nature, structural complexity, and potential behavior in biological contexts [91].](https://figures.cochat.ai/paper-figures/85896b4f34ab4a24b9787b4a09323f06/adiporons-impact-on-alzheimers-diseasea-systematic-review-and-meta-analysis-figure-1.jpg)

![Figure 3 Meta-analysis for overall effects of AdipoRon on novel object preference [99,102].](https://figures.cochat.ai/paper-figures/967fc847edb04f83ba7e8a43a096c0d1/adiporons-impact-on-alzheimers-diseasea-systematic-review-and-meta-analysis-figure-3.jpg)
![Figure 4 Meta-analysis for overall effects of AdipoRon on time spent in the novel arm [100,102].](https://figures.cochat.ai/paper-figures/08a4dd2995a74a4bbea17ac1bacf756b/adiporons-impact-on-alzheimers-diseasea-systematic-review-and-meta-analysis-figure-4.jpg)
![Figure 5 Meta-analysis for overall effects of AdipoRon on time spent in the target quadrant [100,101,102].](https://figures.cochat.ai/paper-figures/1678195445784af1a3d66f21e5dc3f32/adiporons-impact-on-alzheimers-diseasea-systematic-review-and-meta-analysis-figure-5.jpg)
![Figure 6 Meta-analysis for overall effects of AdipoRon on total arm entries [98,100].](https://figures.cochat.ai/paper-figures/50d052ad2bcf43da976526708ba8bd40/adiporons-impact-on-alzheimers-diseasea-systematic-review-and-meta-analysis-figure-6.jpg)
![Figure 7 Meta-analysis for overall effects of AdipoRon on escape latency [98,99,100,101].](https://figures.cochat.ai/paper-figures/2dabb579da9c4ce482e35d4e0adc99a2/adiporons-impact-on-alzheimers-diseasea-systematic-review-and-meta-analysis-figure-7.jpg)
![Figure 8 Meta-analysis for overall effects of AdipoRon on swimming speed [99,100].](https://figures.cochat.ai/paper-figures/c0bcb40479694244be77e35054e97fbd/adiporons-impact-on-alzheimers-diseasea-systematic-review-and-meta-analysis-figure-8.jpg)
![Figure 9 Meta-analysis for overall effects of AdipoRon on crossing times [98,99].](https://figures.cochat.ai/paper-figures/05fc3ef1d46140b097d9fcbae21c557e/adiporons-impact-on-alzheimers-diseasea-systematic-review-and-meta-analysis-figure-9.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated postsynaptic activity triggers BDNF release and TrkB receptor activation, which in turn engages mechanistic target of rapamycin complex 1 (mTORC1) dependent translational programs supporting dendritic spine growth and synaptic strengthening [20,42,48,49,50].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [50]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · cited 1×
“We interpreted 0–40% as unimportant, 30–60% as moderate heterogeneity, 50–75% as substantial heterogeneity, and 75–100% as considerable heterogeneity [94,95].”
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763 · cited 1×
“We interpreted 0–40% as unimportant, 30–60% as moderate heterogeneity, 50–75% as substantial heterogeneity, and 75–100% as considerable heterogeneity [94,95].”
Analysing data and undertaking meta‐analyses
Deeks, J. J., Higgins, J. P., Altman, D. G., & on behalf of the Cochrane Statistical Methods Group (2019) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9781119536604.ch10 · Cited by 2,672 · cited 1×
“We imposed a random-effect model, as this more conservative method permitted the study heterogeneity to deviate beyond chance, providing further generalizable results [96].”
AMPK: Mechanisms of Cellular Energy Sensing and Restoration of Metabolic Balance
Garcia, D., & Shaw, R. J. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.05.032 · Cited by 1,978 · cited 2×
“…stress responses [83,84]. studies have shown that AdipoRon can activate similar signaling pathways to adiponectin, such as the Adenosine Monophosphate ‐ Activated Protein Kinase (AMPK) pathway [74,77,79–82], which plays a role in regulating energy metabolism and cellular stress responses [83,84].”
The Amyloid-β Pathway in Alzheimer’s Disease
Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01249-0 · Cited by 1,952
The blood–brain barrier: Structure, regulation and drug delivery
Wu, D., Chen, Q., Chen, X., Han, F., Chen, Z., & Wang, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01481-w · Cited by 1,906 · cited 1×
“Furthermore, AdipoRon’s ability to regulate autophagy is significant, as autophagic dysfunction is implicated in the accumulation of toxic protein aggregates and cellular debris, exacerbating neurodegenerative processes.”
Adiponectin as an anti-inflammatory factor
Ouchi, N., & Walsh, K. (2007) · Clinica Chimica Acta · doi:10.1016/j.cca.2007.01.026 · Cited by 872
A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity
Okada-Iwabu, M., Yamauchi, T., Iwabu, M., Honma, T., Hamagami, K.-I., Matsuda, K., Yamaguchi, M., Tanabe, H., Kimura-Someya, T., Shirouzu, M., et al. (2013) · Nature · doi:10.1038/nature12656 · Cited by 757
Alzheimer's Disease: Treatment Strategies and Their Limitations.
Passeri, E., Elkhoury, K., Morsink, M., Broersen, K., Linder, M., Tamayol, A., Malaplate, C., Yen, F. T., & Arab-Tehrany, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213954 · Cited by 689 · cited 1×
“This complex and progressive disease disrupts daily functioning and quality of life for millions worldwide, underscoring the urgent need for innovative and effective treatment strategies [29–31].”
Adiponectin: action, regulation and association to insulin sensitivity
Lihn, A. S., Pedersen, S. B., & Richelsen, B. (2005) · Obesity Reviews · doi:10.1111/j.1467-789x.2005.00159.x · Cited by 660 · cited 2×
“Adiponectin’s actions include enhancing insulin sensitivity [54–57], reducing in fl ammation [55,56,58–61], and promoting neuronal survival [62–64], all of which are bene fi cial for maintaining brain health and function [65–69].”
Hippocampus and its involvement in Alzheimer’s disease: a review
Rao, Y. L., Ganaraja, B., Murlimanju, B. V., Joy, T., Krishnamurthy, A., & Agrawal, A. (2022) · 3 Biotech · doi:10.1007/s13205-022-03123-4 · Cited by 573
The role of adipokines in health and disease
Clemente-Suárez, V. J., Redondo-Flórez, L., Beltrán-Velasco, A. I., Martín-Rodríguez, A., Martínez-Guardado, I., Navarro-Jiménez, E., Laborde-Cárdenas, C. C., & Tornero-Aguilera, J. F. (2023) · Biomedicines · doi:10.3390/biomedicines11051290 · Cited by 463
Gómez-Virgilio, L., Silva-Lucero, M.-D.-C., Flores-Morelos, D.-S., Gallardo-Nieto, J., Lopez-Toledo, G., Abarca-Fernandez, A.-M., Zacapala-Gómez, A.-E., Luna-Muñoz, J., Montiel-Sosa, F., Soto-Rojas, L. O., et al. (2022) · Cells · doi:10.3390/cells11152262 · Cited by 431
Insulin and Insulin Resistance in Alzheimer’s Disease
Sędzikowska, A., & Szablewski, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189987 · Cited by 377
Adiponectin: Role in Physiology and Pathophysiology
Nguyen, T. M. D. (2020) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_193_20 · Cited by 366 · cited 1×
“Adiponectin is a hormone secreted by adipose tissue that is well-regarded for its role in regulating metabolic processes such as glucose homeostasis and fatty acid oxidation [41–44].”
The Pivotal Role of NF-kB in the Pathogenesis and Therapeutics of Alzheimer’s Disease
Sun, E., Motolani, A., Campos, L., & Lu, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23168972 · Cited by 361 · cited 1×
“Addressing these limitations through further research will be crucial in determining the clinical viability of AdipoRon and its potential to modify AD progression while addressing both symptomatic relief and underlying pathophysiological mechanisms.”
Adiponectin: Structure, Physiological Functions, Role in Diseases, and Effects of Nutrition
Khoramipour, K., Chamari, K., Hekmatikar, A. A., Ziyaiyan, A., Taherkhani, S., Elguindy, N. M., & Bragazzi, N. L. (2021) · Nutrients · doi:10.3390/nu13041180 · Cited by 336 · cited 2×
“…and Adiponectin Receptor 2 (AdipoR2), which are involved in modulating critical cellular processes [ These receptors activate downstream signaling pathways that regulate inflammation, oxidative stress, and mitochondrial function—crucial factors in neurodegenerative diseases like Alzheimer’s [52,53].”
Alzheimer’s Disease: An Update and Insights Into Pathophysiology
Abubakar, M. B., Sanusi, K. O., Ugusman, A., Mohamed, W., Kamal, H., Ibrahim, N. H., Khoo, C. S., & Kumar, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.742408 · Cited by 279
Insulin Resistance and Alzheimer’s Disease: Bioenergetic Linkages
Neth, B. J., & Craft, S. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00345 · Cited by 272 · cited 1×
“Third, given the promising preclinical results, there is a pressing need for well-designed clinical trials to evaluate the safety and efficacy of AdipoRon in human populations.”
Nishikito, D. F., Borges, A. C. A., Laurindo, L. F., Otoboni, A. M. M. B., Direito, R., Goulart, R. D. Á., Nicolau, C. C. T., Fiorini, A. M. R., Sinatora, R. V., & Barbalho, S. M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010159 · Cited by 199
Self-citationAdipokines: masterminds of metabolic inflammation
Tilg, H., Ianiro, G., Gasbarrini, A., & Adolph, T. E. (2025) · Nature Reviews Immunology · doi:10.1038/s41577-024-01103-8 · Cited by 192
Role of Adiponectin in Central Nervous System Disorders
Bloemer, J., Pinky, P. D., Govindarajulu, M., Hong, H., Judd, R., Amin, R. H., Moore, T., Dhanasekaran, M., Reed, M. N., & Suppiramaniam, V. (2018) · Neural Plasticity · doi:10.1155/2018/4593530 · Cited by 182
NF-κB as a Key Mediator of Brain Inflammation in Alzheimer’s Disease
Ju Hwang, C., Choi, D.-Y., Park, M. H., & Hong, J. T. (2019) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527316666170807130011 · Cited by 178
A Systematic Review of Glucose Transport Alterations in Alzheimer's Disease
Kyrtata, N., Emsley, H. C. A., Sparasci, O., Parkes, L. M., & Dickie, B. R. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.626636 · Cited by 171
Lawther, B. K., Kumar, S., & KROVVIDI, H. P. (2011) · Continuing Education in Anaesthesia Critical Care & Pain · doi:10.1093/bjaceaccp/mkr018 · Cited by 168 · cited 1×
“Furthermore, AdipoRon’s ability to regulate autophagy is significant, as autophagic dysfunction is implicated in the accumulation of toxic protein aggregates and cellular debris, exacerbating neurodegenerative processes.”
Laurindo, L. F., Santos, A. R. D. O. D., Carvalho, A. C. A. D., Bechara, M. D., Guiguer, E. L., Goulart, R. D. A., Vargas Sinatora, R., Araújo, A. C., & Barbalho, S. M. (2023) · Metabolites · doi:10.3390/metabo13010096 · Cited by 166
Self-citationGluT4: A central player in hippocampal memory and brain insulin resistance
McNay, E. C., & Pearson-Leary, J. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2019.113076 · Cited by 153 · cited 1×
“Addressing these limitations through further research will be crucial in determining the clinical viability of AdipoRon and its potential to modify AD progression while addressing both symptomatic relief and underlying pathophysiological mechanisms.”
Valotto Neto, L. J., Reverete de Araujo, M., Moretti Junior, R. C., Mendes Machado, N., Joshi, R. K., dos Santos Buglio, D., Barbalho Lamas, C., Direito, R., Fornari Laurindo, L., Tanaka, M., et al. (2024) · Antioxidants · doi:10.3390/antiox13040393 · Cited by 146
Self-citationFornari Laurindo, L., Aparecido Dias, J., Cressoni Araújo, A., Torres Pomini, K., Machado Galhardi, C., Rucco Penteado Detregiachi, C., Santos de Argollo Haber, L., Donizeti Roque, D., Dib Bechara, M., Vialogo Marques de Castro, M., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1305933 · Cited by 144
Self-citationLee, M.-H., Klein, R. L., El-Shewy, H. M., Luttrell, D. K., & Luttrell, L. M. (2008) · Biochemistry · doi:10.1021/bi801451f · Cited by 129 · cited 2×
“50,51].”
Vinuesa, Á., Pomilio, C. J., Gregosa, A., Bentivegna, M., Presa, J., Bellotto, M., Saravia, F., & Beauquis, J. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.653651 · Cited by 122 · cited 1×
“Addressing these limitations through further research will be crucial in determining the clinical viability of AdipoRon and its potential to modify AD progression while addressing both symptomatic relief and underlying pathophysiological mechanisms.”
Laurindo, L. F., de Carvalho, G. M., de Oliveira Zanuso, B., Figueira, M. E., Direito, R., de Alvares Goulart, R., Buglio, D. S., & Barbalho, S. M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010229 · Cited by 122
Self-citationAdiponectin association with T‐cadherin protects against neointima proliferation and atherosclerosis
Fujishima, Y., Maeda, N., Matsuda, K., Masuda, S., Mori, T., Fukuda, S., Sekimoto, R., Yamaoka, M., Obata, Y., Kita, S., et al. (2017) · The FASEB Journal · doi:10.1096/fj.201601064r · Cited by 119 · cited 1×
“…studies elucidated that adiponectin binding to T-cadherin protects against neointima proliferation and atherosclerosis, which protects individuals against dementia since atherosclerosis is intimately associated with the occurrence of AD [71,72]. isoforms, but not trimeric or spherical forms [70].”
How Can Insulin Resistance Cause Alzheimer’s Disease?
Yoon, J. H., Hwang, J., Son, S. U., Choi, J., You, S.-W., Park, H., Cha, S.-Y., & Maeng, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043506 · Cited by 116
Ng, R. C.-L., Jian, M., Ma, O. K.-F., Bunting, M., Kwan, J., Zhou, G.-J., Krishnamoorthi, S., Iyaswamy, A., Chan, P., Li, M., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0701-0 · Cited by 103 · cited 2×
“Addressing these limitations through further research will be crucial in determining the clinical viability of AdipoRon and its potential to modify AD progression while addressing both symptomatic relief and underlying pathophysiological mechanisms.”
The Novel Perspectives of Adipokines on Brain Health
Lee, T. H.-Y., Cheng, K. K.-Y., Hoo, R. L.-C., Siu, P. M.-F., & Yau, S.-Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225638 · Cited by 100 · cited 1×
“Investigations reported that dysregulated adipokine secretion underlines the co-occurrence of comorbidities such as metabolic syndromes and neurodegenerative diseases [14–22].”
Alzheimer’s disease as type 3 diabetes: understanding the link and implications
Kciuk, M., Kruczkowska, W., Gałęziewska, J., Wanke, K., Kałuzińska-Kołat, Ż., Aleksandrowicz, M., & Kontek, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252211955 · Cited by 98
Komleva, Y. K., Chernykh, A., Lopatina, O. L., Gorina, Y. V., Lokteva, I., Salmina, A. B., & Gollasch, M. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.618395 · Cited by 88
Adipokines in obesity and metabolic-related-diseases
Pestel, J., Blangero, F., Watson, J., Pirola, L., & Eljaafari, A. (2023) · Biochimie · doi:10.1016/j.biochi.2023.04.008 · Cited by 77
Vascular Impairment, Muscle Atrophy, and Cognitive Decline: Critical Age-Related Conditions
de Lima, E. P., Tanaka, M., Lamas, C. B., Quesada, K., Detregiachi, C. R. P., Araújo, A. C., Guiguer, E. L., Catharin, V. M. C. S., de Castro, M. V. M., Junior, E. B., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12092096 · Cited by 73
Self-citationAdiponectin alleviated Alzheimer‐like pathologies via autophagy‐lysosomal activation
He, K., Nie, L., Ali, T., Wang, S., Chen, X., Liu, Z., Li, W., Zhang, K., Xu, J., Liu, J., et al. (2021) · Aging Cell · doi:10.1111/acel.13514 · Cited by 72 · cited 1×
“As AdipoRon may affect multiple cellular processes, its use in combination with other drugs could lead to interactions that alter the efficacy or safety profile of the treatment.”
Liu, B., Liu, J., Wang, J., Liu, C., & Yan, H. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113249 · Cited by 71 · cited 1×
“Despite the promising results, each study presents limitations, including the reliance on specific animal models and the need for validation in diverse and long-term human trials.”
Curcumin: A Golden Approach to Healthy Aging: A Systematic Review of the Evidence
Nunes, Y. C., Mendes, N. M., Pereira de Lima, E., Chehadi, A. C., Lamas, C. B., Haber, J. F. S., dos Santos Bueno, M., Araújo, A. C., Catharin, V. C. S., Detregiachi, C. R. P., et al. (2024) · Nutrients · doi:10.3390/nu16162721 · Cited by 69 · cited 1×
“Additionally, AdipoRon has been observed to influence autophagy [31,82,85–88], a process critical for clearing neurotoxic proteins and maintaining cellular homeostasis [27,89,90].”
Self-citationPagotto, G. L. D. O., Santos, L. M. O. D., Osman, N., Lamas, C. B., Laurindo, L. F., Pomini, K. T., Guissoni, L. M., Lima, E. P. D., Goulart, R. D. A., Catharin, V. M. C. S., et al. (2024) · Antioxidants · doi:10.3390/antiox13060651 · Cited by 67
Self-citationKhandelwal, M., Manglani, K., Upadhyay, P., Azad, M., & Gupta, S. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105876 · Cited by 64 · cited 2×
“Additionally, future research could investigate the development of user-friendly delivery systems for AdipoRon, such as oral formulations or transdermal patches, which would improve patient adherence and reduce the treatment burden.”
The Role of Resveratrol in Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review
Buglio, D. S., Marton, L. T., Laurindo, L. F., Guiguer, E. L., Araújo, A. C., Buchaim, R. L., Goulart, R. D. A., Rubira, C. J., & Barbalho, S. M. (2022) · Journal of Medicinal Food · doi:10.1089/jmf.2021.0084 · Cited by 62
Self-citationTanaka, M., Szabó, Á., & Vécsei, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312767 · Cited by 58
Self-citationNon-Alcoholic Steatohepatitis (NASH) and Organokines: What Is Now and What Will Be in the Future
dos Santos, J. P. M., de Maio, M. C., Lemes, M. A., Laurindo, L. F., Haber, J. F. D. S., Bechara, M. D., do Prado, P. S., Rauen, E. C., Costa, F., Pereira, B. C. D. A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23010498 · Cited by 56 · cited 2×
“…and Adiponectin Receptor 2 (AdipoR2), which are involved in modulating critical cellular processes [ These receptors activate downstream signaling pathways that regulate inflammation, oxidative stress, and mitochondrial function—crucial factors in neurodegenerative diseases like Alzheimer’s [52,53].”
Self-citationMinniti, G., Pescinini-Salzedas, L. M., Minniti, G. A. D. S., Laurindo, L. F., Barbalho, S. M., Sinatora, R. V., Sloan, L. A., Haber, R. S. D. A., Araújo, A. C., Quesada, K. R., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113452 · Cited by 56
Self-citationAssociation between atherosclerosis and Alzheimer's disease: A systematic review and meta‐analysis
Xie, B.-J., Shi, X.-R., Xing, Y., & Tang, Y. (2020) · Brain and Behavior · doi:10.1002/brb3.1601 · Cited by 53 · cited 1×
“…studies elucidated that adiponectin binding to T-cadherin protects against neointima proliferation and atherosclerosis, which protects individuals against dementia since atherosclerosis is intimately associated with the occurrence of AD [71,72]. isoforms, but not trimeric or spherical forms [70].”
The Interaction Between NF-κB and Estrogen in Alzheimer’s Disease
Mishra, P., Davies, D. A., & Albensi, B. C. (2023) · Molecular Neurobiology · doi:10.1007/s12035-022-03152-3 · Cited by 51
Insulin resistance in Alzheimer’s disease: The genetics and metabolomics links
Amin, A. M., Mostafa, H. M. A., & Khojah, H. M. J. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2022.12.016 · Cited by 51 · cited 1×
“Addressing these limitations through further research will be crucial in determining the clinical viability of AdipoRon and its potential to modify AD progression while addressing both symptomatic relief and underlying pathophysiological mechanisms.”
Interplay between the brain and adipose tissue: a metabolic conversation
Díaz‐Castro, F., Morselli, E., & Claret, M. (2024) · EMBO Reports · doi:10.1038/s44319-024-00321-4 · Cited by 49
Adipokines at the crossroads of obesity and mesenchymal stem cell therapy
Pham, D., Nguyen, T.-K., & Park, P. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-00940-2 · Cited by 48
Jászberényi, M., Thurzó, B., Bagosi, Z., Vécsei, L., & Tanaka, M. (2024) · Biomedicines · doi:10.3390/biomedicines12020448 · Cited by 47
Self-citationThe Mechanism of Leptin Resistance in Obesity and Therapeutic Perspective
Engin, A. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-63657-8_16 · Cited by 47
AdipoRon and Other Adiponectin Receptor Agonists as Potential Candidates in Cancer Treatments
Nigro, E., Daniele, A., Salzillo, A., Ragone, A., Naviglio, S., & Sapio, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115569 · Cited by 46 · cited 2×
“AdipoRon (Figure 1), a synthetic adiponectin receptor agonist, was developed to replicate and amplify these bene fi cial e ff ects [73–78].”
Barbalho, S. M., Méndez‐Sánchez, N., & Laurindo, L. F. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115871 · Cited by 46
Self-citationBattaglia, S., Avenanti, A., Vécsei, L., & Tanaka, M. (2024) · Biomedicines · doi:10.3390/biomedicines12030574 · Cited by 45 · cited 1×
“Addressing these limitations through further research will be crucial in determining the clinical viability of AdipoRon and its potential to modify AD progression while addressing both symptomatic relief and underlying pathophysiological mechanisms.”
Self-citationAdiponectin Role in Neurodegenerative Diseases: Focus on Nutrition Review
Polito, R., Meo, I. D., Barbieri, M., Daniele, A., Paolisso, G., & Rizzo, M. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239255 · Cited by 44
Organokines in Rheumatoid Arthritis: A Critical Review
Laurindo, L. F., de Maio, M. C., Barbalho, S. M., Guiguer, É. L., Araújo, A. C., Goulart, R. D. Á., Flato, U. A. P., Baldi, E., Detregiachi, C. R. P., Haber, J. F. D. S., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116193 · Cited by 44
Self-citationNeural Correlates and Molecular Mechanisms of Memory and Learning
Battaglia, S., Avenanti, A., Vécsei, L., & Tanaka, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052724 · Cited by 44 · cited 1×
“Addressing these limitations through further research will be crucial in determining the clinical viability of AdipoRon and its potential to modify AD progression while addressing both symptomatic relief and underlying pathophysiological mechanisms.”
Self-citationNeuropsychobiology of fear-induced bradycardia in humans: progress and pitfalls
Battaglia, S., Nazzi, C., Lonsdorf, T. B., & Thayer, J. F. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02600-x · Cited by 44
Innovation at the Intersection: Emerging Translational Research in Neurology and Psychiatry
Tanaka, M., Battaglia, S., Giménez-Llort, L., Chen, C., Hepsomali, P., Avenanti, A., & Vécsei, L. (2024) · Cells · doi:10.3390/cells13100790 · Cited by 44
Self-citationCabinio, M., Saresella, M., Piancone, F., LaRosa, F., Marventano, I., Guerini, F. R., Nemni, R., Baglio, F., & Clerici, M. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-180250 · Cited by 39
Lee, T. H.-Y., Ahadullah, Christie, B. R., Lin, K., Parco Ming-fai, S. I. U., Zhang, L., Yuan, T., Komal, P., Xu, A., So, K., et al. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02441-7 · Cited by 38 · cited 1×
“Addressing these limitations through further research will be crucial in determining the clinical viability of AdipoRon and its potential to modify AD progression while addressing both symptomatic relief and underlying pathophysiological mechanisms.”
Nazzi, C., Avenanti, A., & Battaglia, S. (2024) · Antioxidants · doi:10.3390/antiox13060701 · Cited by 37 · cited 2×
“Adiponectin’s actions include enhancing insulin sensitivity [54–57], reducing in fl ammation [55,56,58–61], and promoting neuronal survival [62–64], all of which are bene fi cial for maintaining brain health and function [65–69].”
Bridging the gap: glucose transporters, Alzheimer’s, and future therapeutic prospects
Albaik, M., Saleh, D. S., Kauther, D., Mohammed, H., Alfarra, S., Alghamdi, A., Ghaboura, N., & Sindi, I. A. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1344039 · Cited by 36 · cited 1×
“Addressing these limitations through further research will be crucial in determining the clinical viability of AdipoRon and its potential to modify AD progression while addressing both symptomatic relief and underlying pathophysiological mechanisms.”
Wu, X., Luo, J., Liu, H., Cui, W., Guo, W., Zhao, L., Guo, H., Bai, H., Guo, K., Feng, D., et al. (2020) · Cell Proliferation · doi:10.1111/cpr.12759 · Cited by 35 · cited 2×
“Adiponectin’s actions include enhancing insulin sensitivity [54–57], reducing in fl ammation [55,56,58–61], and promoting neuronal survival [62–64], all of which are bene fi cial for maintaining brain health and function [65–69].”
Selvais, C. M., de Carrizosa, M. A. D., Nachit, M., Versele, R., Dubuisson, N., Noël, L., Gillard, J., Leclercq, I. A., Brichard, S. M., & Abou‐Samra, M. (2022) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13148 · Cited by 35 · cited 1×
“Investigations into the pharmacokinetics and pharmacodynamics of AdipoRon could offer insights into effective dosing strategies and potential interactions with other medications commonly used in Alzheimer’s treatment.”
AdipoRon Treatment Induces a Dose-Dependent Response in Adult Hippocampal Neurogenesis
Lee, T. H.-Y., Christie, B. R., van Praag, H., Lin, K., Parco Ming-fai, S. I. U., Xu, A., So, K., & Yau, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042068 · Cited by 34 · cited 1×
“Furthermore, AdipoRon’s ability to regulate autophagy is significant, as autophagic dysfunction is implicated in the accumulation of toxic protein aggregates and cellular debris, exacerbating neurodegenerative processes.”
From Lab to Life: Exploring Cutting-Edge Models for Neurological and Psychiatric Disorders
Tanaka, M., & Vécsei, L. (2024) · Biomedicines · doi:10.3390/biomedicines12030613 · Cited by 34
Self-citationNovel therapeutic approaches to target neurodegeneration
de la Fuente, A. G., Pelucchi, S., Mertens, J., Luca, M. D., Mauceri, D., & Marcello, E. E. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16078 · Cited by 33
The Indissociable Triad: Vascular Impairment, Muscle Atrophy, and Cognitive DeclinePreprint
de Lima, E. P., Tanaka, M., Lamas, C. B., et al. (2024) · Preprints.org · doi:10.20944/preprints202408.0728.v1 · Cited by 33
Self-citationNatale, F., Spinelli, M., Rinaudo, M., Gulisano, W., Sarrapochiello, I. N., Aceto, G., Puzzo, D., Fusco, S., & Grassi, C. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2402604121 · Cited by 33
Wang, C., Chang, Y., Zhu, J., Wu, Y., Jiang, X., Zheng, S., Li, G., & Ma, R. (2023) · Experimental Neurology · doi:10.1016/j.expneurol.2023.114355 · Cited by 32 · cited 1×
“Such comprehensive research efforts will help establish AdipoRon’s role in AD treatment and contribute to its potential translation into clinical practice.”
NF-κB in Alzheimer’s Disease: Friend or Foe? Opposite Functions in Neurons and Glial Cells
Kaltschmidt, B., Czaniera, N. J., Schulten, W., & Kaltschmidt, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111353 · Cited by 30
A Decade of Dedication: Pioneering Perspectives on Neurological Diseases and Mental Illnesses
Tanaka, M., & Vécsei, L. (2024) · Biomedicines · doi:10.3390/biomedicines12051083 · Cited by 28 · cited 1×
“In recent years, AD research has increasingly focused on novel therapeutic approaches targeting underlying metabolic and neurodegenerative processes [32–36].”
Self-citationDuan, Z., Tu, C., Liu, Q., Li, S., Li, Y., Xie, P., & Li, Z. (2020) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29605 · Cited by 27
Formolo, D. A., Lee, T. H., Yu, J., Lin, K., Chen, G., Kranz, G. S., & Yau, S. (2023) · Biomedicines · doi:10.3390/biomedicines11020249 · Cited by 27
Inflammatory Manifestations Associated With Gut Dysbiosis in Alzheimer’s Disease
Kozhakhmetov, S., Kaiyrlykyzy, A., Jarmukhanov, Z., Vinogradova, E. B., Zholdasbekova, G., Alzhanova, D., Kunz, J., Kushugulova, A. R., & Askarova, S. (2024) · International Journal of Alzheimer s Disease · doi:10.1155/2024/9741811 · Cited by 27
Shi, X., Jiang, A., Qiu, Z., Lin, A., Liu, Z., Zhu, L., Mou, W., Cheng, Q., Zhang, J., Miao, K., et al. (2024) · Frontiers of Medicine · doi:10.1007/s11684-024-1094-2 · Cited by 27
Mapping and engineering the interaction between adiponectin and T-cadherin
Pascolutti, R., Erlandson, S. C., Burri, D. J., Zheng, S., & Kruse, A. C. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.010970 · Cited by 26 · cited 2×
“This protein Besides its complex structure, T-cadherin only binds to the hexametric and high molecular weight adiponectin isoforms, but not trimeric or spherical forms [70]. lacks transmembrane and cytoplasmic regions.”
Organokines in COVID-19: A Systematic Review
Barbalho, S. M., Minniti, G., Miola, V. F. B., Haber, J. F. D. S., Bueno, P. C. D. S., Haber, L. S. D. A., Gírio, R. J. S., Detregiachi, C. R. P., Dall’Antonia, C., Rodrigues, V. D., et al. (2023) · Cells · doi:10.3390/cells12101349 · Cited by 26
Self-citationBattaglia, S., Avenanti, A., Vécsei, L., et al. (2024) · Preprints.org · doi:10.20944/preprints202402.0879.v1 · Cited by 26
Obesity-induced neuronal senescence: Unraveling the pathophysiological links
Ghosh, P., Fontanella, R. A., Scisciola, L., Taktaz, F., Pesapane, A., Basilicata, M. G., Tortorella, G., Matacchione, G., Capuano, A., Vietri, M. T., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102533 · Cited by 25
Shishkina, G. T., Kalinina, T. S., Gulyaeva, N. V., Lanshakov, D. A., & Дыгало, Н. Н. (2021) · Biochemistry (Moscow) · doi:10.1134/s0006297921060043 · Cited by 24
Panov, G., Dyulgerova, S., & Panova, P. (2023) · Biomedicines · doi:10.3390/biomedicines11123114 · Cited by 24 · cited 1×
“Addressing these limitations through further research will be crucial in determining the clinical viability of AdipoRon and its potential to modify AD progression while addressing both symptomatic relief and underlying pathophysiological mechanisms.”
Innovation at the Intersection: Emerging Translational Research in Neurology and PsychiatryPreprint
Tanaka, M., Battaglia, S., Giménez‐Llort, L., et al. (2024) · Preprints.org · doi:10.20944/preprints202404.1130.v1 · Cited by 24
Self-citationFrom Lab to Life: Exploring Cutting-Edge Models for Neurological and Psychiatric DisordersPreprint
Tanaka, M., & Vécsei, L. (2024) · Preprints.org · doi:10.20944/preprints202403.0259.v1 · Cited by 22
Self-citationTanaka, M., & Vécsei, L. (2024) · Journal of Neural Transmission · doi:10.1007/s00702-024-02812-z · Cited by 22 · cited 1×
“Alzheimer’s disease (AD) stands as one of the most pressing challenges in neurodegenerative disorders, characterized by a relentless decline in cognitive function and the accumulation of pathological proteins such as Amyloid-Beta (A β ) plaques and hyper-phosphorylated tau tangles [23–28].”
Self-citationAPOE ε4, the door to insulin‐resistant dyslipidemia and brain fog? A case study
Stoykovich, S., & Gibas, K. J. (2019) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.01.009 · Cited by 22
Pharmacological and physiological roles of adipokines and myokines in metabolic-related dementia
Arjunan, A., & Song, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114847 · Cited by 21
Tolédano, A., Rodríguez‐Casado, A., Álvarez, M., & Toledano‐Díaz, A. (2024) · Brain Sciences · doi:10.3390/brainsci14111101 · Cited by 21 · cited 1×
“Third, given the promising preclinical results, there is a pressing need for well-designed clinical trials to evaluate the safety and efficacy of AdipoRon in human populations.”
Duquenne, M., Deligia, E., Folgueira, C., Bourouh, C., Caron, É., Pfrieger, F. W., Schwaninger, M., Nogueiras, R., Annicotte, J., Imbernón, M., et al. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.101996 · Cited by 20
Laurindo, L. F., Sosin, A. F., Lamas, C. B., Goulart, R. D. Á., Haber, J. F. D. S., Detregiachi, C. R. P., & Barbalho, S. M. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02792-z · Cited by 19 · cited 1×
“One promising strategy involves AdipoRon, a synthetic agonist that activates the adiponectin receptor [37–40].”
Self-citationLiu, Y., Fu, X., Sun, J., Cui, R., & Yang, W. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113011 · Cited by 19
Samaha, M. M., El-Desoky, M. M., & Hisham, F. A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112395 · Cited by 18
Azizifar, N., Mohaddes, G., Keyhanmanesh, ., Athari, S. Z., Alimohammadi, S., & Farajdokht, F. (2024) · Neurochemical Research · doi:10.1007/s11064-024-04223-8 · Cited by 18 · cited 1×
“Addressing these limitations through further research will be crucial in determining the clinical viability of AdipoRon and its potential to modify AD progression while addressing both symptomatic relief and underlying pathophysiological mechanisms.”
Molecular mechanisms of obesity predisposes to atopic dermatitis
Shang, D., & Zhao, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1473105 · Cited by 18 · cited 2×
“Adiponectin’s actions include enhancing insulin sensitivity [54–57], reducing in fl ammation [55,56,58–61], and promoting neuronal survival [62–64], all of which are bene fi cial for maintaining brain health and function [65–69].”
Wang, Y., Liu, H., Zhang, R., Xiang, Y., Lu, J. F., Xia, B., Peng, L., & Wu, J. W. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101641 · Cited by 17
Tanaka, M., Szabó, Á., & Vécsei, L. (2024) · Preprints.org · doi:10.20944/preprints202410.1193.v2 · Cited by 17
Self-citationMa, O. K.-F., Ronsisvalle, S., Basile, L., Xiang, A. W., Tomasella, C., Sipala, F. M., Pappalardo, M., Chan, K., Milardi, D., Ng, R. C.-L., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114141 · Cited by 16
Sun, F., Wang, J., Meng, L., Zhou, Z., Xu, Y., Yang, M., Li, Y., Jiang, T., Liu, B., & Yan, H. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16400 · Cited by 16 · cited 2×
“Differences in genetic backgrounds, disease progression, and comorbidities can affect how well these models translate to human outcomes [140–145].”
Phenotypic and functional disparities in perivascular adipose tissue
Guo, E., Liu, D., & Zhu, Z. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2024.1499340 · Cited by 16 · cited 1×
“Adiponectin is a hormone secreted by adipose tissue that is well-regarded for its role in regulating metabolic processes such as glucose homeostasis and fatty acid oxidation [41–44].”
ANGPTL4-mediated microglial lipid droplet accumulation: Bridging Alzheimer's disease and obesity
Li, N., Wang, X., Lin, R., Yang, F., Chang, H.-C., Gu, X., Shu, J., Liu, G., Yu, Y., Wei, W., et al. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106741 · Cited by 16
Leptin bioavailability and markers of brain atrophy and vascular injury in the middle age
Charisis, S., Short, M. I., Bernal, R., Kautz, T. F., Trevino, H., Mathews, J. J., Velarde, A. G., Muhammad, J. A. S., Luckey, A. M., Aslam, A., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13879 · Cited by 15
The role of novel inflammation-associated biomarkers in diabetic peripheral neuropathy
Panou, T., Gouveri, E., Papazoglou, D., & Παπάνας, Ν. (2024) · Metabolism Open · doi:10.1016/j.metop.2024.100328 · Cited by 15
Abosharaf, H. A., Elsonbaty, Y., Tousson, E., & Mohamed, T. M. (2024) · Metabolic Brain Disease · doi:10.1007/s11011-024-01422-8 · Cited by 15
Malicka-Durczak, A., Ali, A., MacCannell, A. D. V., & Roberts, L. D. (2024) · Experimental Physiology · doi:10.1113/ep092008 · Cited by 15
Laurindo, L. F., Laurindo, L. F., Rodrigues, V. D., Catharin, V. M. C. S., Simili, O. A. G., Barboza, G. D. O., Catharin, V. C. S., Sloan, K. P., & Barbalho, S. M. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03362-7 · Cited by 14
Self-citationZhao, W., Zhang, W. Y., Hu, Y., Zhou, Y., Zhao, J., Li, Y., & Xu, Z. (2024) · Neurochemical Research · doi:10.1007/s11064-024-04162-4 · Cited by 13 · cited 1×
“Addressing these limitations through further research will be crucial in determining the clinical viability of AdipoRon and its potential to modify AD progression while addressing both symptomatic relief and underlying pathophysiological mechanisms.”
García‐García, I., Kamal, F., Donica, O., Dadar, M., & Initiative, A. D. N. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111077 · Cited by 13
Li, C., Zhang, J., Dionigi, G., Liang, N., Guan, H., & Sun, H. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07084-9 · Cited by 13
Valencia‐Ortega, J., Castillo-Santos, A., Molerés-Orduña, M., Solis‐Paredes, J. M., Saucedo, R., Estrada‐Gutiérrez, G., & Camacho‐Arroyo, I. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111655 · Cited by 13
Goli, S. H., Lim, J.-Y., Basaran-Akgul, N., & Templeton, S. P. (2025) · PLoS Pathogens · doi:10.1371/journal.ppat.1012363 · Cited by 13
Wojciuk, B., Frulenko, I., Brodkiewicz, A., Kita, D., Baluta, M. M., Jędrzejczyk, F., Budkowska, M., Turkiewicz, K., Proia, P., Ciechanowicz, A., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111608 · Cited by 12 · cited 2×
“Adiponectin’s actions include enhancing insulin sensitivity [54–57], reducing in fl ammation [55,56,58–61], and promoting neuronal survival [62–64], all of which are bene fi cial for maintaining brain health and function [65–69].”
“OMICS” in Human Milk: Focus on Biological Effects on Bone Homeostasis
Farella, I., D’Amato, G., Orellana‐Manzano, A., Segura, Y., Vitale, R., Clodoveo, M. L., Corbo, F., & Faienza, M. F. (2024) · Nutrients · doi:10.3390/nu16223921 · Cited by 11
Permana, A. D., Mahfud, M. A. S., Munir, M., Aries, A., Putra, A. R., Fikri, A., Setiawan, H., Mahendra, I., Rizaludin, A., Aziz, A. Y. R., et al. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c16024 · Cited by 11
Carbone, G., Bencivenga, L., Santoro, M. A., Lucia, N. D., Palaia, M. E., Ercolano, E., Scognamiglio, F., Edison, P., Ferrara, N., Vitale, D. F., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1389014 · Cited by 10
Alimohammadi, S., Mohaddes, G., Keyhanmanesh, ., Athari, S. Z., Azizifar, N., & Farajdokht, F. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110180 · Cited by 10
Metabolic obesity phenotypes and thyroid cancer risk: A systematic exploration of the evidence
Hedayati, M., Valizadeh, M., & Abiri, B. (2024) · Obesity Science & Practice · doi:10.1002/osp4.70019 · Cited by 9
Barbalho, S. M., Pomini, K. T., de Lima, E. P., Oliveira, J. D. S. C., Boaro, B. L., Araújo, A. C., Guiguer, É. L., Rici, R. E. G., Maria, D. A., Haber, J. F. D. S., et al. (2024) · Cancers · doi:10.3390/cancers16223758 · Cited by 9 · cited 1×
“Additionally, AdipoRon has been observed to influence autophagy [31,82,85–88], a process critical for clearing neurotoxic proteins and maintaining cellular homeostasis [27,89,90].”
Self-citationJabeen, K., Rehman, K., Akash, M. S. H., Hussain, A., Shahid, M., & Sadaf, B. (2024) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.70007 · Cited by 9
Challenging Sarcopenia: Exploring AdipoRon in Aging Skeletal Muscle as a Healthspan-Extending Shield
Selvais, C. M., de Carrizosa, M. A. D., Versele, R., Dubuisson, N., Noël, L., Brichard, S. M., & Abou‐Samra, M. (2024) · Antioxidants · doi:10.3390/antiox13091073 · Cited by 8 · cited 4×
“…can activate similar signaling pathways to adiponectin, such as the Adenosine Monophosphate-Activated Protein Kinase (AMPK) pathway [74,77,79–82], which plays a role in regulating energy metabolism and cellular stress responses [83,84]. studies have shown that AdipoRon can activate similar…”
InfluentialMartínez-Cignoni, M. R., González-Vicens, A., Morán-Costoya, A., Amengual-Cladera, E., Gianotti, M., Valle, A., Proenza, A. M., & Lladó, I. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.09.001 · Cited by 8
Chu, J. M. T., Chiu, S. P. W., Wang, J., Chang, R. C., & Wong, G. T. C. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00954-0 · Cited by 8
A Cross-Sectional Study: Systematic Quantification of Chemerin in Human Cerebrospinal Fluid
Höpfinger, A., Behrendt, M., Schmid, A., Karrasch, T., Schäffler, A., & Berghoff, M. (2024) · Biomedicines · doi:10.3390/biomedicines12112508 · Cited by 8
Shao, X., Pan, X., Chen, T., Chen, Z., Li, Y., Zhong, J., Wang, R., Yu, J., Chen, J., & Chen, Y. (2024) · Acta Dermato Venereologica · doi:10.2340/actadv.v104.41018 · Cited by 8
Chen, T., Shuang, R., Gao, T., Ai, L., Diao, J., Yuan, X., He, L., Tao, W., & Huang, X. (2024) · Journal of Pineal Research · doi:10.1111/jpi.70010 · Cited by 8 · cited 2×
“…Protein Kinase (AMPK) pathway [74,77,79–82], which plays a role in regulating energy metabolism and cellular stress responses [83,84]. studies have shown that AdipoRon can activate similar signaling pathways to adiponectin, such as the Adenosine Monophosphate ‐ Activated Protein…”
Luo, Z., Wu, A., Robson, S. C., Alper, S. L., & Yu, W. (2025) · JCI Insight · doi:10.1172/jci.insight.188780 · Cited by 8
Mahmoodi, M., Dahagi, E. M., Nabavi, M.-H., Penalva, Y. C. M., Gosaine, A., Murshed, M., Couldwell, S., Munter, L. M., & Kaartinen, M. T. (2024) · Physiological Reports · doi:10.14814/phy2.16152 · Cited by 7
Circulating adipokines and MRI markers of brain aging in middle-aged adults from the community
Satizábal, C., Himali, J., Conner, S., Beiser, A., Maillard, P., Vasan, R., Decarli, C., & Seshadri, S. (2024) · Journal of Alzheimer's Disease · doi:10.1177/13872877241289043 · Cited by 7
Hunyenyiwa, T., Kyi, P., Scheer, M., Joshi, M., Gasparri, M., Mammoto, T., & Mammoto, A. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1491971 · Cited by 6
Liu, Y., Xu, Y., Ji, H., Gao, F., Ge, R., Zhou, D., Fu, H., Liu, X., & Ma, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011277 · Cited by 6
Athari, S. Z., Keyhanmanesh, ., Farajdokht, F., Karimipour, M., Azizifar, N., Alimohammadi, S., & Mohaddes, G. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177111 · Cited by 6 · cited 2×
“…stress responses [83,84]. studies have shown that AdipoRon can activate similar signaling pathways to adiponectin, such as the Adenosine Monophosphate ‐ Activated Protein Kinase (AMPK) pathway [74,77,79–82], which plays a role in regulating energy metabolism and cellular stress responses [83,84].”
The Potential Therapeutic Use of Agarwood for Diabetes: A Scoping Review
Fadzil, M. A. M., Seman, N. A., & Rashed, A. A. (2024) · Pharmaceuticals · doi:10.3390/ph17111548 · Cited by 6
dos Santos, J. R., Catalão, C. H. R., Vulczak, A., Azzolini, A. E. C. S., & Alberici, L. C. (2024) · Journal of Alzheimer s Disease · doi:10.1177/13872877241289388 · Cited by 6
Laurindo, L. F., Minniti, G., Rodrigues, V. D., Laurindo, L. F., Catharin, V. M. C. S., Chagas, E. F. B., dos Anjos, V. D., de Castro, M. V. M., Baldi, E., Sanches, R. C. F., et al. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673308301240821052742 · Cited by 5
Self-citationEffect of goose-derived adiponectin peptide gADP3 on LPS-induced inflammatory injury in goose liver
Ma, B., Zheng, Y., Liu, S., Qiu, Y., Xing, X., Gao, M., Cao, Z., & Luan, X. (2024) · British Poultry Science · doi:10.1080/00071668.2024.2393960 · Cited by 5
Laurindo, L. F., Laurindo, L. F., Rodrigues, V. D., Chagas, E. F. B., Oliveira, J. D. S. C., Catharin, V. M. C. S., & Barbalho, S. M. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03441-9 · Cited by 5 · cited 2×
“Addressing these limitations through further research will be crucial in determining the clinical viability of AdipoRon and its potential to modify AD progression while addressing both symptomatic relief and underlying pathophysiological mechanisms.”
Self-citationClimacosa, F. M. M., Anlacan, V. M. M., Gordovez, F. J. A., Reyes, J. C. B., Tabios, I. K. B., Manalo, R. V. M., Cruz, J. M. C., Asis, J. L. B., Razal, R. B., Abaca, M. J. M., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-078660 · Cited by 5
Feng, J., Ma, X., Liu, Y., Shi, X., Jin, L., Le, Y., Zhang, Q., & Wang, C. (2024) · Environmental Science & Technology · doi:10.1021/acs.est.4c07051 · Cited by 4
The role of adiponectin-AMPK axis in TDP-43 mislocalization and disease severity in ALS
Liu, Y., Lee, C.-W., Liao, Y., Huang, J. J., Kuo, H., Jih, K., Lee, Y., & Chern, Y. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106715 · Cited by 4 · cited 2×
“Adiponectin’s actions include enhancing insulin sensitivity [54–57], reducing in fl ammation [55,56,58–61], and promoting neuronal survival [62–64], all of which are bene fi cial for maintaining brain health and function [65–69].”
Li, C., Li, Q., Wu, X., Zhang, Z., Li, J., Jiang, R., Li, G., Liu, X., Kang, X., Li, Z., et al. (2024) · Poultry Science · doi:10.1016/j.psj.2024.104538 · Cited by 4
Affliction class moderates the dementing impact of adipokines.
Royall, D. R., & Palmer, R. F. (2024) · Neuropsychology · doi:10.1037/neu0000968 · Cited by 4
Serum Leucine-Rich Alpha-2 Glycoprotein 1 Levels in Patients with Lipodystrophy Syndromes
Krienke, M., Kralisch, S., Wagner, L., Tönjes, A., & Miehle, K. (2024) · Biomolecules · doi:10.3390/biom14111474 · Cited by 4
Quantitative Proteomic Analysis of APP/PS1 Transgenic Mice
Wang, J., Wang, X., An, Z., Wang, X., Wang, Y., Lu, Y., Qiu, M. S., Liu, Z., & Tan, Z. (2024) · Current Alzheimer Research · doi:10.2174/0115672050345431241113112608 · Cited by 3
Adiponectin Signaling Modulates Fat Taste Responsiveness in Mice
Lin, F., Masterson, E., & Gilbertson, T. A. (2024) · Nutrients · doi:10.3390/nu16213704 · Cited by 3 · cited 2×
“…AdipoRon can activate similar signaling pathways to adiponectin, such as the Adenosine Monophosphate-Activated Protein Kinase (AMPK) pathway [74,77,79–82], which plays a role in regulating energy metabolism and cellular stress responses [83,84]. studies have shown that AdipoRon can activate…”
Goli, S. H., Lim, J.-Y., Basaran-Akgul, N., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.24.600373 · Cited by 2
The Role of Lymph-Adipose Crosstalk in Alcohol-Induced Perilymphatic Adipose Tissue Dysfunction
Weaver, K. D., Simon, L., Molina, P. E., & Souza‐Smith, F. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910811 · Cited by 2 · cited 1×
“Investigations reported that dysregulated adipokine secretion underlines the co-occurrence of comorbidities such as metabolic syndromes and neurodegenerative diseases [14–22].”
APOE Genotype and Biological Age Impact Inter-Omic Associations Related to BioenergeticsPreprint
Ellis, D., Watanabe, K., Wilmanski, T. M., Lustgarten, M. S., Korat, A. V. A., Glusman, G., Hadlock, J., Fiehn, O., Paola Sebastiani, B., Price, N. D., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.17.618322 · Cited by 2
Luo, Z., Wu, A., Robson, S. C., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.25.620328 · Cited by 2
Pathogenesis and Neuroendocrine Immunology
Straub, R. H. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-803321-0.00002-1 · Cited by 1
Duraipandy, N., Ekambaram, S., Tarantini, S., Nagaraja, R. Y., Yabluchanskiy, A., Hedrick, A. F., Awasthi, V., Subramanian, M., Csiszár, A., & Balasubramanian, P. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.09.602747 · Cited by 1 · cited 1×
“Evidence has demonstrated that adipokines such as adiponectin cross the blood-brain barrier, and it is known that the neurotrophic and anti-inflammatory properties of adipokines drive their neuroprotective effects against neurodegeneration [8–13].”
Adiponectin signaling modulates fat taste responsiveness in micePreprint
Lin, F., Masterson, E., & Gilbertson, T. A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.05.611494 · Cited by 1
Research works printed but not linked: 1
- (2024, July 22). National Library of Medicine, National Library of Medicine-National Institute of Health. AdipoRon, Available online: https://pubchem.ncbi.nlm.nih.gov/compound/AdipoRon.
Cited by
de Lima, E. P., Laurindo, L. F., Catharin, V. C. S., Direito, R., Tanaka, M., Jasmin Santos German, I., Lamas, C. B., Guiguer, E. L., Araújo, A. C., Fiorini, A. M. R., et al. (2025) · Metabolites · doi:10.3390/metabo15020124 · Cited by 94
Self-citationParkinson’s Disease: Bridging Gaps, Building Biomarkers, and Reimagining Clinical Translation
Tanaka, M. (2025) · Cells · doi:10.3390/cells14151161 · Cited by 56
Self-citationParkinson’s Disease: Bridging Gaps, Building Biomarkers, and Reimagining Clinical Translation
Tanaka, M. (2025) · doi:10.20944/preprints202506.2099.v2 · Cited by 57
Self-citationNeuroinflammation and Natural Antidepressants: Balancing Fire with Flora
Figueiredo Godoy, A. C., Frota, F. F., Araújo, L. P., Valenti, V. E., Pereira, E. D. S. B. M., Detregiachi, C. R. P., Galhardi, C. M., Caracio, F. C., Haber, R. S. A., Fornari Laurindo, L., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13051129 · Cited by 32
Self-citationQuinoline Quest: Kynurenic Acid Strategies for Next-Generation Therapeutics via Rational Drug Design
Tanaka, M., Szatmári, I., & Vécsei, L. (2025) · Pharmaceuticals · doi:10.3390/ph18050607 · Cited by 29
Self-citation
Metadata
- Authors
- Barbalho, S. M., Laurindo, L. F., de Oliveira Zanuso, B., da Silva, R. M. S., Gallerani Caglioni, L., Nunes Junqueira de Moraes, V. B. F., Fornari Laurindo, L., Dogani Rodrigues, V., da Silva Camarinha Oliveira, J., Beluce, M. E., Penteado Detregiachi, C. R., Barbalho Lamas, C., dos Santos Haber, J. F., Cavallari Strozze Catharin, V. M., Quesada, K., Tanaka, M., & Valenti, V. E.
- Affiliations
- São Paulo State Technological College (BR)
- Faculdade de Medicina de São José do Rio Preto (BR)
- Department of Biochemistry and Pharmacology, School of Medicine, Universidade de Marília (UNIMAR), Marília 17525-902, São Paulo, Brazil
- Department of Biochemistry and Pharmacology, School of Medicine, Faculdade de Medicina de Marília (FAMEMA), Marília 17519-030, São Paulo, Brazil
- Department of Biochemistry and Pharmacology, School of Medicine, Faculdade de Medicina de São José do Rio Preto (FAMERP), São José do Rio Preto 15090-000, São Paulo, Brazil
- Universidade de Marília (BR)
- Department of Gerontology, School of Gerontology, Universidade Federal de São Carlos (UFSCar), São Carlos 13565-905, São Paulo, Brazil
- University of Szeged (HU)
- Autonomic Nervous System Center, School of Philosophy and Sciences, São Paulo State University, Marília 17525-902, São Paulo, Brazil
- Corresponding author
- Tanaka, Masaru
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2025-01-08
- Volume
- 26
- Issue
- 2
- Pages
- 484
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC11765103
- OpenAlex
- W4406170873
- Cited by
- 18
- References
- 148
- Citations by year
- 2026: 6 · 2025: 12
- FWCI
- 2.36
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Preprints.org (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- HUN-REN Hungarian Research Network
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- AdipoRon, adiponectin receptor agonist, Alzheimer's disease, neuroprotection, neuroinflammation, tau hyperphosphorylation, synaptic dysfunction, mitochondrial function, cognitive function, transgenic mouse model, neurodegeneration
- MeSH terms
- Alzheimer Disease, Animals, Disease Models, Animal, Humans, Indenes, Piperidines, tau Proteins, Neuroprotective Agents, Adiponectin, Receptors, Adiponectin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.